Literature DB >> 15149579

Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Maria T. Abreu1.   

Abstract

Crohn's disease and ulcerative colitis (UC) are heterogeneous disorders, and as such, the response to therapy is likewise heterogeneous. Therefore, stratification of patients into distinct phenotypes and potentially genotypes will lead to more definitive answers with respect to evaluation of novel and established therapies.

Entities:  

Year:  2004        PMID： 15149579     DOI： 10.1007/s11938-004-0038-9

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN： 1092-8472


  73 in total

1.  Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha.

Authors:  Denis Franchimont; Jérôme Galon; Melanie S Vacchio; Samuel Fan; Roberta Visconti; David M Frucht; Vincent Geenen; George P Chrousos; Jonathan D Ashwell; John J O'Shea
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

2.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

3.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.

Authors:  C Cuffari; S Hunt; T Bayless
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

4.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease.

Authors:  Suzanne Lesage; Habib Zouali; Jean-Pierre Cézard; Jean-Frédéric Colombel; Jacques Belaiche; Sven Almer; Curt Tysk; Colm O'Morain; Miquel Gassull; Vibeke Binder; Yigael Finkel; Robert Modigliani; Corinne Gower-Rousseau; Jeanne Macry; Françoise Merlin; Mathias Chamaillard; Anne-Sophie Jannot; Gilles Thomas; Jean-Pierre Hugot
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

7.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

8.  Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

Authors:  W J Sandborn; B E Sands; D C Wolf; J F Valentine; M Safdi; S Katz; K L Isaacs; L D Wruble; J Katz; D H Present; E V Loftus; F Graeme-Cook; D J Odenheimer; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2003-06-01       Impact factor: 8.171

9.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

10.  Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes.

Authors:  Timothy R Orchard; C N Chua; Tariq Ahmad; Hung Cheng; Kenneth I Welsh; Derek P Jewell
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.